Submit Deal

VENTYX BIOSCIENCES

Summary

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 907 M

Avg. Deal Size£ 454 M

Market Context

Senior Management

Raju Mohan
CEO
Alex Schwartz
Vice President, Strategic Finance and Investor Relations

Sort

23 Sep 2024|United States|Biotechnology

Target: VENTYX BIOSCIENCES

Bidder: SANOFI SA

3 Service Providers

2 Target | 1 Bidder

6 Dealmakers

2 Target | 4 Bidder

£ 20 M

Value

07 Jan 2026|United States|Biotechnology

Target: VENTYX BIOSCIENCES

Bidder: ELI LILLY AND COMPANY

8 Service Providers

5 Target | 3 Bidder

10 Dealmakers

7 Target | 3 Bidder

£ 887 M

Value